following an abbreviated submission:
fluticasone propionate/ formoterol fumarate (Flutiform k-haler®) is accepted for use within NHSScotland.
Indication under review: for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA)] is appropriate:
• For patients not adequately controlled with ICS as ‘as required’ inhaled short-acting β2-agonist or
• For patients already adequately controlled on both ICS and a LABA
Flutiform k-haler is a breath-actuated inhaler that is bioequivalent to Flutiform metered-dose inhaler (pMDI) and costs the same.
To read more Press Release articles, click here.